NKX2-1

Across TCGA pan-cancer cohorts, NKX2-1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated NKX2-1 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher NKX2-1 Mutation is associated with better overall survival. In most high-consensus cancer types, elevated NKX2-1 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

STAD, PRAD, and UCEC are the cancer types where NKX2-1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	III,IV	1.000	0.360	.024	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

NKX2-1–STAD (OS)

Open the STAD breakdown →